These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37127479)

  • 41. Analysis of CT, MRI imaging features of renal cell carcinoma with different histopathological types.
    Wang X; Kong W; Wang Y; Wang Y; Chen Y; Shi Z; Liu Y
    J BUON; 2021; 26(5):2053-2058. PubMed ID: 34761616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma.
    Beck SD; Patel MI; Snyder ME; Kattan MW; Motzer RJ; Reuter VE; Russo P
    Ann Surg Oncol; 2004 Jan; 11(1):71-7. PubMed ID: 14699037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma.
    An J; Packiam VT; Chennamadhavuni A; Richards J; Jain J; Mott SL; Garje R
    Front Oncol; 2021; 11():786307. PubMed ID: 35083144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Percutaneous radiofrequency ablation for renal cell carcinoma vs. partial nephrectomy: Comparison of long-term oncologic outcomes in both clear cell and non-clear cell of the most common subtype.
    Liu N; Huang D; Cheng X; Chong Y; Wang W; Gan W; Guo H
    Urol Oncol; 2017 Aug; 35(8):530.e1-530.e6. PubMed ID: 28408296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.
    Leibovich BC; Lohse CM; Cheville JC; Zaid HB; Boorjian SA; Frank I; Thompson RH; Parker WP
    Eur Urol; 2018 May; 73(5):772-780. PubMed ID: 29398265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DYSF expression in clear cell renal cell carcinoma: A retrospective study of 2 independent cohorts.
    Ha M; Jeong H; Roh JS; Lee B; Han ME; Oh SO; Sohn DH; Kim YH
    Urol Oncol; 2019 Oct; 37(10):735-741. PubMed ID: 31377166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
    Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
    J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
    Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
    J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma.
    Chen F; Huhdanpaa H; Desai B; Hwang D; Cen S; Sherrod A; Bernhard JC; Desai M; Gill I; Duddalwar V
    Springerplus; 2015; 4():66. PubMed ID: 25694862
    [TBL] [Abstract][Full Text] [Related]  

  • 52. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
    Peng Y; Greenland NY; Lang UE; Stohr BA
    Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
    Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
    BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
    Wang J; Xi Z; Xi J; Zhang H; Li J; Xia Y; Yi Y
    Cancer Cell Int; 2018; 18():159. PubMed ID: 30349421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases.
    Maas M; Kurcz A; Hennenlotter J; Scharpf M; Fend F; Walz S; Stühler V; Todenhöfer T; Stenzl A; Bedke J; Rausch S
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.
    Erlmeier F; Sun N; Shen J; Feuchtinger A; Buck A; Prade VM; Kunzke T; Schraml P; Moch H; Autenrieth M; Weichert W; Hartmann A; Walch A
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries.
    Marquardt A; Solimando AG; Kerscher A; Bittrich M; Kalogirou C; Kübler H; Rosenwald A; Bargou R; Kollmannsberger P; Schilling B; Meierjohann S; Krebs M
    Front Oncol; 2021; 11():621278. PubMed ID: 33791209
    [No Abstract]   [Full Text] [Related]  

  • 58. A Protective Role for Androgen Receptor in Clear Cell Renal Cell Carcinoma Based on Mining TCGA Data.
    Zhao H; Leppert JT; Peehl DM
    PLoS One; 2016; 11(1):e0146505. PubMed ID: 26814892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
    Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
    Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
    Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
    BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.